Novartis yanks imatinib PAH NDA; FDA wants more data, cancels AdCom
This article was originally published in Scrip
The first sign there may be trouble with Novartis' new drug application (NDA) for imatinib as a pulmonary arterial hypertension (PAH) treatment came on 15 August when the US FDA called off the 14 September meeting of its Cardiovascular and Renal Drugs Advisory Committee, although regulators declined to disclose the trigger for the cancellation.
You may also be interested in...
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.